Biofluidica

Chapel Hill, United States Founded: 2007 • Age: 19 yrs
Liquid biopsy tests utilizing CTCs are provided for cancer detection.
Request Access

About Biofluidica

Biofluidica is a company based in Chapel Hill (United States) founded in 2007 by Steven A Soper.. Biofluidica has raised $18.12 million across 11 funding rounds from investors including NIH, HHS and Mizzou. Biofluidica offers products and services including LiquidScan, Exosome Isolation, Fetal Cell Isolation, and CTC Isolation. Biofluidica operates in a competitive market with competitors including Guardant Health, GRAIL, Thrive Earlier Detection, Delfi Diagnostics and Abingdon Health, among others.

  • Headquarter Chapel Hill, United States
  • Founders Steven A Soper
  • Sectors
    Healthcare
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Biofluidica, Inc.
Operational Areas
Healthcare → Biotechnology, Genomics & Life Sciences Research
Healthcare → Biotechnology, Genomics & Life Sciences Research
Healthcare → Healthcare Products & Supplies
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $18.12 M (USD)

    in 11 rounds

  • Latest Funding Round
  • Investors
    NIH

    & 2 more

  • Employee Count
    Employee Count
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of Biofluidica

Biofluidica offers a comprehensive portfolio of products and services, including LiquidScan, Exosome Isolation, Fetal Cell Isolation, and CTC Isolation. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

Automates isolation of rare cells and exosomes for diagnostics

Enables exosome extraction from samples for research analysis

Facilitates isolation of trophoblasts for prenatal testing

Supports isolation of circulating tumor cells from blood

Funding Insights of Biofluidica

Biofluidica has successfully raised a total of $18.12M across 11 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 11
  • Last Round
  • First Round

    (17 Sep 2015)

  • Investors Count 3
Date Amount Transaction Name Valuation Lead Investors Investors
Mar, 2022 Amount Grant - Biofluidica Valuation

investors

Dec, 2021 Amount Series B - Biofluidica Valuation

investors

Aug, 2021 Amount Grant - Biofluidica Valuation

investors

NIH
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Biofluidica

Biofluidica has secured backing from 3 investors, including institutional investors. Prominent investors backing the company include NIH, HHS and Mizzou. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Institutional
Investor Description Founded Year Domain Location
Multiple courses and degrees are offered across diversified academic streams.
Founded Year Domain Location
Drug discovery services are provided to the biopharma sector.
Founded Year Domain Location
Public health and human services are overseen by HHS.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Biofluidica

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - Biofluidica

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Biofluidica Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Biofluidica

Biofluidica operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Guardant Health, GRAIL, Thrive Earlier Detection, Delfi Diagnostics and Abingdon Health, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Digital sequencing technology for cancer detection is developed.
domain founded_year HQ Location
Circulating tumor DNA is screened for early cancer detection.
domain founded_year HQ Location
Blood-based liquid biopsy tests for multiple cancer detection are provided.
domain founded_year HQ Location
Provider of DNA sequencing for cancer detection
domain founded_year HQ Location
Developer of immunoassays for diagnostic purposes
domain founded_year HQ Location
Provider of cell-free cancer liquid biopsy test
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Frequently Asked Questions about Biofluidica

When was Biofluidica founded?

Biofluidica was founded in 2007 and raised its 1st funding round 8 years after it was founded.

Where is Biofluidica located?

Biofluidica is headquartered in Chapel Hill, United States. It is registered at Chapel Hill, North Carolina, United States.

Who is the current CEO of Biofluidica?

Greg Studdard is the current CEO of Biofluidica.

Is Biofluidica a funded company?

Biofluidica is a funded company, having raised a total of $18.12M across 11 funding rounds to date. The company's 1st funding round was a Grant of $250K, raised on Sep 17, 2015.

What does Biofluidica do?

Biofluidica was founded in 2007 and is based in Chapel Hill, United States, within the biotechnology sector. Operations focus on liquid biopsy systems that employ antibody-coated capture beds to isolate circulating tumor cells from blood samples. Clinical validation has been achieved for pancreatic, colorectal, ovarian, and breast cancers, enabling analysis for diagnostic purposes.

Who are the top competitors of Biofluidica?

Biofluidica's top competitors include Guardant Health, GRAIL and BillionToOne.

What products or services does Biofluidica offer?

Biofluidica offers LiquidScan, Exosome Isolation, Fetal Cell Isolation, and CTC Isolation.

Who are Biofluidica's investors?

Biofluidica has 3 investors. Key investors include NIH, HHS, and Mizzou.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available